Zafgen Inc. (NASDAQ:ZFGN)‘s stock had its “hold” rating reissued by equities researchers at FBR & Co in a research report issued to clients and investors on Tuesday.

Several other brokerages have also issued reports on ZFGN. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Tuesday, July 26th. Cowen and Company reiterated a “buy” rating and set a $60.00 price target on shares of Zafgen in a report on Thursday, August 25th. Canaccord Genuity set a $4.00 price target on Zafgen and gave the company a “hold” rating in a report on Thursday, July 21st. Finally, Leerink Swann reiterated a “market perform” rating and set a $6.00 price target on shares of Zafgen in a report on Wednesday, July 20th. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $14.22.

Shares of Zafgen (NASDAQ:ZFGN) traded down 1.50% during mid-day trading on Tuesday, reaching $3.29. 1,451,759 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $3.13 and a 200-day moving average price of $5.42. Zafgen has a 1-year low of $2.90 and a 1-year high of $44.98. The company’s market capitalization is $89.91 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zafgen-inc-zfgn-receives-hold-rating-from-fbr-co.html

In other Zafgen news, CFO Patricia L. Allen purchased 16,000 shares of the business’s stock in a transaction dated Tuesday, July 26th. The stock was bought at an average cost of $3.12 per share, for a total transaction of $49,920.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Frances K. Heller purchased 10,000 shares of the business’s stock in a transaction dated Friday, July 22nd. The shares were acquired at an average price of $2.99 per share, with a total value of $29,900.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $29,900. The disclosure for this purchase can be found here. Insiders own 20.30% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of ZFGN. ProShare Advisors LLC raised its position in shares of Zafgen by 4.9% in the second quarter. ProShare Advisors LLC now owns 23,099 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 1,075 shares during the period. Alps Advisors Inc. raised its position in shares of Zafgen by 25.1% in the second quarter. Alps Advisors Inc. now owns 38,312 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 7,683 shares during the period. Geode Capital Management LLC raised its position in shares of Zafgen by 10.3% in the first quarter. Geode Capital Management LLC now owns 128,152 shares of the biopharmaceutical company’s stock worth $856,000 after buying an additional 11,965 shares during the period. California State Teachers Retirement System raised its position in shares of Zafgen by 33.8% in the second quarter. California State Teachers Retirement System now owns 47,925 shares of the biopharmaceutical company’s stock worth $287,000 after buying an additional 12,104 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Zafgen by 103.0% in the second quarter. Rhumbline Advisers now owns 34,692 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 17,602 shares during the period. Institutional investors own 62.83% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

5 Day Chart for NASDAQ:ZFGN

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.